NCT06173505 2026-03-13
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Xencor, Inc.
Phase 1/2 Terminated
Xencor, Inc.
Hoffmann-La Roche
Akeso
Hoffmann-La Roche
Thomas Jefferson University
University of Michigan Rogel Cancer Center
University of Pittsburgh